VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 158 filers reported holding VERVE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $120,839 | +633.2% | 24,762 | +1895.3% | 0.00% | – |
| Q1 2024 | $16,480 | -14.9% | 1,241 | -10.7% | 0.00% | – |
| Q4 2023 | $19,362 | -31.2% | 1,389 | -34.5% | 0.00% | -100.0% |
| Q3 2023 | $28,124 | -57.7% | 2,121 | -40.2% | 0.00% | -50.0% |
| Q2 2023 | $66,544 | +73025.3% | 3,549 | -44.0% | 0.00% | -33.3% |
| Q1 2023 | $91 | -21.6% | 6,333 | +6.0% | 0.00% | -40.0% |
| Q4 2022 | $116 | -99.9% | 5,974 | -2.7% | 0.01% | +66.7% |
| Q3 2022 | $211,000 | +502.9% | 6,139 | +164.2% | 0.00% | +200.0% |
| Q2 2022 | $35,000 | -59.8% | 2,324 | -39.2% | 0.00% | 0.0% |
| Q1 2022 | $87,000 | -59.7% | 3,824 | -34.6% | 0.00% | -75.0% |
| Q4 2021 | $216,000 | +315.4% | 5,849 | +431.7% | 0.00% | +300.0% |
| Q3 2021 | $52,000 | – | 1,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $37,665,169 | 23.26% |
| Alphabet Inc. | 10,549,086 | $197,795,362 | 10.63% |
| Casdin Capital, LLC | 2,360,571 | $44,260,706 | 3.87% |
| MPM BioImpact LLC | 857,940 | $16,086,375 | 3.24% |
| Redmile Group, LLC | 1,061,960 | $19,911,750 | 0.76% |
| Novo Holdings A/S | 500,000 | $9,375,000 | 0.72% |
| ARK Investment Management | 5,150,851 | $96,578,455 | 0.64% |
| Avidity Partners Management LP | 878,600 | $16,473,750 | 0.58% |
| Nikko Asset Management Americas, Inc. | 2,185,857 | $40,941,102 | 0.43% |
| Cormorant Asset Management, LP | 350,000 | $6,562,500 | 0.37% |